SCHEMBL5084404

SCHEMBL5084404

COc1ccc(CCC(=O)c2c(O)cc(OC)cc2O)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NFKB1 P19838 2/20 1.00
NFKB2 Q00653 2/20 1.00
RELA Q04206 2/20 1.00
SLC5A1 P13866 8/20 0.91
SLC5A2 P31639 7/20 0.91
CYP19A1 P11511 3/20 0.66
GAA P10253 2/20 0.66
MAPT P10636 2/20 0.66
CYP3A4 P08684 2/20 0.66
CYP2D6 P10635 2/20 0.66
CYP2C19 P33261 2/20 0.66
KDM4E B2RXH2 1/20 0.66
MEN1 O00255 1/20 0.66
SLC16A3 O15427 1/20 0.66
ALDH1A1 P00352 1/20 0.66
LMNA P02545 1/20 0.66
TTR P02766 1/20 0.66
ESR1 P03372 1/20 0.66
TP53 P04637 1/20 0.66
CYP1A2 P05177 1/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL457127 0.95 SLC5A1 (1.00) NFKB1NFKB2RELASLC5A1SLC5A2
Asebogenin SCHEMBL4740064 0.94 NFKB1 (0.88) NFKB1NFKB2RELASLC5A1SLC5A2
SCHEMBL2282039 0.91 NFKB1 (0.83) NFKB1NFKB2RELASLC5A1SLC5A2
SCHEMBL15457885 0.91 NFKB1 (0.83) NFKB1NFKB2RELASLC5A1SLC5A2
SCHEMBL1682159 0.91 NFKB1 (0.83) NFKB1NFKB2RELASLC5A1SLC5A2
SCHEMBL4742840 0.89 NFKB1 (0.80) NFKB1NFKB2RELASLC5A1SLC5A2
SCHEMBL15457887 0.88 NFKB1 (0.78) NFKB1NFKB2RELASLC5A1SLC5A2
SCHEMBL8115827 0.87 NFKB1 (0.77) NFKB1NFKB2RELASLC5A1SLC5A2
SCHEMBL1938352 0.87 SLC5A1 (0.84) NFKB1NFKB2RELASLC5A1SLC5A2
SCHEMBL11293573 0.86 NFKB1 (0.75) NFKB1NFKB2RELASLC5A1SLC5A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260048027-A1 METHYLATED PHLORETIN ANALOGS AS INHIBITORS OF SGLT2 NESTLE SA (CH) 2026-02-19 US claimed
EP-4655410-A2 O-METHYLATION OF PHENOLIC SUBSTANCES VIA FUNGAL O-METHYLTRANSFERASE Symrise AG (DE) 2025-12-03 EP claimed
EP-4572749-A1 METHYLATED PHLORETIN ANALOGS AS INHIBITORS OF SGLT2 Société des Produits Nestlé S.A. (CH) 2025-06-25 EP claimed
WO-2024156359-A1 O-METHYLATION OF PHENOLIC SUBSTANCES VIA FUNGAL O-METHYLTRANSFERASE SYMRISE AG (DE) 2024-08-02 WO claimed
WO-2024156879-A2 O-METHYLATION OF PHENOLIC SUBSTANCES VIA FUNGAL O-METHYLTRANSFERASE SYMRISE AG (DE) 2024-08-02 WO claimed
WO-2024038011-A1 METHYLATED PHLORETIN ANALOGS AS INHIBITORS OF SGLT2 Société des Produits Nestlé S.A. (CH) 2024-02-22 WO claimed
EP-4747367-A1 NEW ENZYMES FOR THE MANUFACTURING OF 4'-O-METHYLATED PHENOLIC SUBSTANCES Symrise AG (DE) 2026-05-27 EP disclosed
US-20260048027-A1 METHYLATED PHLORETIN ANALOGS AS INHIBITORS OF SGLT2 NESTLE SA (CH) 2026-02-19 US disclosed
EP-4655410-A2 O-METHYLATION OF PHENOLIC SUBSTANCES VIA FUNGAL O-METHYLTRANSFERASE Symrise AG (DE) 2025-12-03 EP disclosed
EP-4572749-A1 METHYLATED PHLORETIN ANALOGS AS INHIBITORS OF SGLT2 Société des Produits Nestlé S.A. (CH) 2025-06-25 EP disclosed
CN-119654142-A Methylated phloretin analogs as inhibitors of SGLT2 雀巢产品有限公司 2025-03-18 CN disclosed
WO-2025017042-A1 NEW ENZYMES FOR THE MANUFACTURING OF 4'-O-METHYLATED PHENOLIC SUBSTANCES SYMRISE AG (DE) 2025-01-23 WO disclosed
WO-2025016533-A1 NEW ENZYMES FOR THE MANUFACTURING OF 4'-O-METHYLATED PHENOLIC SUBSTANCES SYMRISE AG (DE) 2025-01-23 WO disclosed
WO-2024038011-A1 METHYLATED PHLORETIN ANALOGS AS INHIBITORS OF SGLT2 Société des Produits Nestlé S.A. (CH) 2024-02-22 WO disclosed
CN-109890376-A Composition is used in PGC-1 α activation 三得利控股株式会社 2019-06-14 CN disclosed
WO-2017132135-A1 ESTROGEN RECEPTOR ALPHA COLIGANDS, AND METHODS OF USE THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2017-08-03 WO disclosed
US-20170071902-A1 NOX INHIBITOR AND NFkB INHIBITOR CONTAINING METHOXYFLAVONE SUNTORY HOLDINGS LIMITED (JP) 2017-03-16 US disclosed
WO-2007115181-A9 COMPOUNDS EXHIBITING EFFLUX INHIBITOR ACTIVITY AND COMPOSITIONS AND USES THEREOF EASTMAN CHEM CO (US) 2008-04-03 WO disclosed
US-20070254859-A1 Compounds exhibiting efflux inhibitor activity and composition and uses thereof EASTMAN CHEMICAL COMPANY 2007-11-01 US disclosed
WO-2007115181-A2 COMPOUNDS EXHIBITING EFFLUX INHIBITOR ACTIVITY AND COMPOSITIONS AND USES THEREOF EASTMAN CHEMICAL COMPANY (US) 2007-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254859-A1 Compounds exhibiting efflux inhibitor activity and composition and uses thereof ABCC4, NCOA4, NR4A3 NFKB1 1115/4885NFKB2 1419/4885RELA 1175/4885
US-20170071902-A1 NOX INHIBITOR AND NFkB INHIBITOR CONTAINING METHOXYFLAVONE NOX1, NFKBIA, NOX5 NFKB1 9/4885NFKB2 8/4885RELA 13/4885
US-20260048027-A1 METHYLATED PHLORETIN ANALOGS AS INHIBITORS OF SGLT2 SLC5A2, SLC5A1, SLC2A1 NFKB1 4036/4885NFKB2 3494/4885RELA 3925/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.